u u u u
OF PULMONARY FUNCTION TESTING
u u u u
11 TH EDITION BYMOTTRAM BRAND
u u u u u u
NEW2024/2025.
u
,Chapter u1: uIndications ufor uPulmonary uFunction uTesting
uTestuBank
MULTIPLE uCHOICE
1. Who ufirst upopularized uspirometry ufor uthe uevaluation uof upulmonary ufunction?
a. August uand uMarie uKrogh
b. Alvan uBarach
c. John uSeveringhaus
d. John uHutchinson
ANS: uD
Hutchinson upopularized uthe uconcept uof uusing uVC uto uassess ulung ufunction, uand uthe
unames uheugave uto useveral uother ulung ucompartments uare ustill uused utoday.
DIF: 1 REF: p. u2 OBJ: None u MSC: uNBRC: uNone
2. Which uof uthe ufollowing uare uindications ufor uperforming uspirometry?
1. Assess uthe urisk uof ulung uresection.
2. Determine uthe uresponse uto ubronchodilator utherapy.
3. Assess uthe useverity uof urestrictive ulung udisease.
4. Quantify uthe uextent uof uCOPD.
a. 1 u and u u4
b. 2 u and u u3
c. 1 u, u2, uand u u4
d. 2 u, u3, uand u u4
ANS: uC
Spirometry ucannot uassess useverity uof urestriction; ufor uthat uyou uneed uto umeasure ulung
uvolumes u(usee uBox u1-2, uChapter u u1).
DIF: 1 REF: p. u7 OBJ: EL-2 MSC: uNBRC: uNone
,3. The umain uindication ufor uthe umeasurement uof ulung uvolumes uis uto udo uwhich uof uthe
ufollowing?
a. Diagnose uor uassess uthe useverity uof urestriction.
b. Evaluate uthe useverity uof upulmonary uhypertension.
c. Determine uthe ulevel uof ucardiopulmonary ufitness.
d. Assess uthe urisk uof uabdominal usurgical uprocedures.
ANS: uA
The umost ucommon ureason ufor umeasuring ulung uvolumes uis uto uidentify urestrictive ulung
udisease.uDIF: 1 REF: p. u35 OBJ: EL-2 MSC: uNBRC: uNone
4. DLCO umeasurements umay ube uindicated uto uevaluate upulmonary uinvolvement uin uwhich
uof utheufollowing usystemic udiseases?
a. Asthma
b. Sarcoidosis
c. Exertional uhypoxemia
, Stuvia.com u- uThe uMarketplace uto uBuy uand uSell uyour
uStudy uMaterial
d. Guillain-Barré usyndrome
ANS: uB
Sarcoidosis uis uthe uonly usystemic udisease ulisted uthat uaffects ugas
uexchange.uDIF: u1 uREF: up. u9 u| up. u19 u| up. u21 u| up. u35 uOBJ: uEL-2
uMSC: uNBRC: uNone
5. Blood ugas uanalysis uis uused uwith upatients uwith uCOPD uto udo
uwhich uof utheufollowing?
a. Monitor uairway uresponsiveness.
b. Determine ulevel uof ucardiopulmonary ufitness.
c. Detect upulmonary uhypertension.
d. Assess uneed ufor usupplementary uO2.
ANS: uD
Blood ugas uanalysis uis umost ucommonly uused uto udetermine uthe uneed ufor usupplemental
uoxygenuand uto umanage upatients uwho urequire uventilatory usupport.
DIF: 2 REF: p. u15 OBJ: EL-1
uMSC: uNBRC: uCPFT u2A-2
6. Which uof uthe ufollowing ucause uemphysema?
1. 1- uAntitrypsin udeficiency
2. Exposure uto uenvironmental upollutants
3. Radiation utherapy
4. Cigarette usmoking
a. 1 u and u u2
b. 3 u and u u4
c. 1 u, u2, uand u u4
d. 2 u, u3, uand u u4
ANS: uC
Emphysema uis ucaused uprimarily uby ucigarette usmoking. uSome uemphysema uis ucaused uby
utheuabsence uof ua uprotective uenzyme. uChronic uexposure uto uenvironmental upollutants ucan
ualso ucontribute uto uthe udevelopment uof uemphysema.
DIF: 1 REF: p. u11 OBJ: EL-3 u| uAL-2 MSC: uNBRC: uNone
7. An uadult upatient ucomplains uof uchest utightness uand ucough uwhenever uhe ujogs uin ucold
uweather.uThese usymptoms uare uconsistent uwith uwhich uof uthe ufollowing?
a. Cystic ufibrosis
b. Asthma
c. Pulmonary uhypertension
d. Idiopathic upulmonary ufibrosis